智通财经APP讯，启明医疗-B(02500)发布公告，于2025年12月29日，卖方启明医疗(香港)有限公司与买方Broncus China Holding Corporation订立股份转让协议，卖方同意出售而买方同意购买销售股份，代价为1500万美元，占被投资公司Valgen Holding Corporation于本公告日期已发行股份总数(按全面摊薄及已转换基准)约1.05%。
被投资公司为根据开曼群岛法律注册成立及存续的获豁免公司。其主要从事为二尖瓣反流、三尖瓣反流等病变提供系统性解决方案。
为优先重新分配资源以发展其核心产品及支持其长期业务增长，本公司持续精简其投资组合及专注于其主要业务营运。作为被投资公司的少数财务投资者，出售事项为本集团变现其投资的适当机会：透过剥离非核心业务投资，本集团将能够加强其现金流，改善其营运资金状况，提升整体财务灵活性，并促进资源重新分配至其核心业务。董事会认为审慎的资本管理(包括本次出售事项)有利于确保本集团的可持续发展及加强股东回报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.